All In Biotech

Drug Trial Radar · NCT01341379

Increasing Ureagenesis in Inborn Errors of Metabolism With N-Carbamylglutamate

Last checked: Nov 20, 2026Latest source record: May 29, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

Withdrawn

Status

Withdrawn

Enrollment

0

Actual

Start

Dec 2010

Primary completion

Aug 2012

Study completion Aug 2012

Sponsor

Lead sponsor
Children's Hospital of PhiladelphiaAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
First posted
Apr 25, 2011

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 3 years, up to 70 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Hyperammonemia, which can cause brain damage, occurs in many different kinds of inborn errors of metabolism. The investigators propose to determine if short-term (3 day) treatment with N-carbamylglutamate can diminish hyperammonemia by enhancing ureagenesis in these patients. The investigators propose here a short-term (3 day) trial. If it succeeds, the investigators would consider more extensive long-term studies of the drug.

Conditions

  • Urea Cycle Disorders, Inborn
  • Inborn Errors of Metabolism
  • Propionic Acidemia
  • Methylmalonic Acidemia
  • Carbamyl Phosphate Synthetase Deficiency

Interventions

  • N-carbamylglutamateDrug

    N-carbamylglutamate: 200 mg/kg/day for 3 days, divided into 4 daily oral doses

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Rate of ureagenesisTime frame: 3 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.